

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Karl Schoenafinger	03/23/2007
Gerhard Jaehne	03/28/2007
Elisabeth Defossa	03/29/2007
Christian Buning	03/29/2007
Georg Tschank	04/03/2007
Ulrich Werner	04/03/2007
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Sanofi-Aventis Deutschland GmbH
<b>Street Address:</b>	Industriepark Hoechst
<b>City:</b>	65929 Frankfurt am Main
<b>State/Country:</b>	GERMANY
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	11674261
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(908)231-2626
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	908-231-2387
Email:	maribel.mendez@sanofi-aventis.com
Correspondent Name:	Craig Bell
Address Line 1:	1041 Route 202-206
Address Line 4:	Bridgewater, NEW JERSEY 08807
ATTORNEY DOCKET NUMBER:	DEAV2004/0056 US CNT
NAME OF SUBMITTER:	Maribel Mendez

CH \$40.00 11674261

Total Attachments: 1

source=DEAV20040056USCNTASSIGNMENT#page1.tif

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Karl Schoenafinger, 63755 Alzenau
- 2) Dr. Gerhard Jaehne, 65929 Frankfurt
- 3) Dr. Elisabeth Defossa, 65510 Idstein
- 4) Dr. Christian Buning, 53175 Bonn
- 5) Dr. Georg Tschank, 55270 Essenheim
- 6) Dr. Ulrich Werner, 56357 Miehlen

The inventors are citizens of: 1) - 4) and 6) Germany; 5) Austria

hereby sell, assign, and transfer unto **Sanofi-Aventis Deutschland GmbH**,  
a corporation organized under the laws of **Germany**,  
located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of  
the United States, executed concurrently herewith

Ser.-No.: **11/674,261**

filed: **February 13, 2007**

entitled: **SUBSTITUTED 8-AMINOALKOXY-XANTHINE COMPOUNDS AND  
COMPOSITIONS USEFUL IN THE TREATMENT OF HYPERLIPIDEMIA  
AND DIABETES**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said  
application for Letters Patent, and in and to all divisional or continuation applications that may  
be filed for United States Letters Patent for any of said inventions, and in and to all patents  
that may be granted on the foregoing applications, and I/we hereby agree, whenever  
requested, to communicate to said assignee, its successors and assigns, any facts known to  
me/us respecting said inventions, to testify in any legal proceeding, and to execute all  
applications or papers necessary to obtain and maintain proper patent protection on said  
inventions in the United States.

**Inventor(s):**

1 <sup>st</sup> :	<u>Karl Schoenafinger</u>	Date: <u>23.03.2007</u>
2 <sup>nd</sup> :	<u>Gerhard Jaehne</u>	Date: <u>28.03.2007</u>
3 <sup>rd</sup> :	<u>Elisabeth Defossa</u>	Date: <u>29.3.2007</u>
4 <sup>th</sup> :	<u>Christian Buning</u>	Date: <u>29/03/2007</u>
5 <sup>th</sup> :	<u>Georg Tschank</u>	Date: <u>03/04/2007</u>
6 <sup>th</sup> :	<u>Ulrich Werner</u>	Date: <u>03/04/2007</u>

**PATENT**